Information Provided By:
Fly News Breaks for December 3, 2019
Dec 3, 2019 | 06:26 EDT
Goldman Sachs analyst Salveen Richter initiated coverage of uniQure with a Buy rating and $98 price target. uniQure is a clinical-stage gene therapy company targeting liver and central nervous system disorders and developed the first commercial gene therapy, Glybera, Richter tells investors in a research note. The analyst is positive on the company's lead program AMT-061 in hemophilia B. Further, he views the Huntington's disease program as the next key value driver with first safety/biomarker data in 2020.
News For QURE From the Last 2 Days
There are no results for your query QURE